Analyst firms · Credit Suisse · ESPR
Credit Suisse ESPR price target and rating history
Esperion Therapeutics Inc. (ESPR) · Health Care
Credit Suisse rates Esperion Therapeutics Inc. (ESPR) Neutral with a $7 price target, as of its latest action on Mar 7, 2023. It has published 5 rating actions on ESPR since October 2021, including 1 upgrade and 2 downgrades.
- Current rating
- Neutral
- Price target
- $7
- Median target, all firms
- Too few
- Actions on ESPR
- 5
Credit Suisse price target on ESPR
Every Credit Suisse rating on ESPR
- Mar 7, 2023
- Aug 3, 2022
- Jan 14, 2022
- Dec 6, 2021
- Oct 19, 2021
How other firms rate ESPR
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| H.C. Wainwright | Neutral | May 1, 2026 | |
| Piper Sandler | Overweight | $9 | Nov 25, 2025 |
Questions about Credit Suisse and ESPR
- What is Credit Suisse's price target for ESPR?
- Credit Suisse's latest stated price target for Esperion Therapeutics Inc. (ESPR) is $7, from its action on Mar 7, 2023.
- What is Credit Suisse's rating on ESPR?
- Credit Suisse rates ESPR Neutral, a neutral rating, as of Mar 7, 2023.
- When did Credit Suisse last change its view on ESPR?
- On Mar 7, 2023, Credit Suisse upgrades to Neutral from Underperform, price target $6.50 to $7.
More ESPR rating histories
All Credit Suisse ratingsESPR news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.